重组人BMP9(GDF2)

特别提示：包括重组人BMP9(GDF2)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人BMP9(GDF2)
英文名称：Recombinant Human Growth and differentiation factor 2/Bone morphogenetic protein 9
产品货号：JN1407
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Ser320-Arg429在C端含有His标签。

BMP9/GDF2质量控制：＞95%(还原性SDS-PAGE)

BMP9/GDF2制剂：冻干品

BMP9/GDF2保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

BMP9/GDF2复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于BMP9/GDF2：
Bone morphogenetic protein 9 (BMP9), also known as growth differentiation factor-2, is a member of the TGFβ superfamily proteins that bind to type II and type I serine-threonine kinase receptors, and transduces signals through Smad and non-Smad signalling pathways. BMP9 has been shown to be a potent synergistic factor for hematopoietic progenitor generation and colony formation and may play a role in the induction and maintenance of the neuronal cholinergic phenotype in the central nervous system. ALK1 and ALK2 are important receptors for BMP9-induced osteogenic differentiation both in vitro and in vivo. BMP9 is highly expressed in the developing mouse liver, and recombinant human BMP9 stimulates hepatocyte proliferation.

除了重组人BMP9(GDF2),，我公司还供应以下相关产品：



名称：重组人趋化因子CCL1(I-309)
货号：JN0303
规格：10μg|50μg|500μg|1mg
本品由我们的大肠杆菌表达系统制备，目的基因编码的Lys24-Lys96表达纯化而来。

CCL1/I-309质量控制：＞95%(还原性SDS-PAGE)。

CCL1/I-309制剂：冻干品

CCL1/I-309保存：
冻干蛋白可在-20℃长期保存，室温也可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天。
复溶后建议分装冻存在-20℃，可保存3个月，应避免反复冻融。

CCL1/I-309复溶：
1、试剂开盖前请先离心。
2、复溶浓度应大于100 μg/ml.
3、冻干蛋白溶于ddH2O中
4、复溶后根据使用量分装保存，避免反复冻融。

关于CCL1/I-309：
Chemokine (C-C Motif) Ligand 1 (CCL1) is a small glycoprotein secreted by activated T cells, which play a central role during immunoregulatory and inflammaion processes. Human CCL1 has been assumed to be a homologue of the mouse TCA3. While the two proteins share only approximately 42% amino acid sequence identity, both chemokines contain an extra pair of cysteine residues not found in most other chemokines. CCL1 attracts monocytes, NK cells, and immature B cells and dendritic cells by interacting with cell surface chemokine receptor CCR8. CCL1 is identified as a potent inhibitor of HIV-1 envelope-mediated cell-cell fusion and virus infection.